Tolerance induction in the adult: 'danger' at Le Bischenberg. by Chatenoud, L, Waldmann, H, Emmrich, F

Delayed Anti-CD3 Therapy Results in Depletion of Alloreactive T Cells and the Dominance of Foxp3+CD4+Graft Infiltrating Cells by Goto, R, You, S, Zaitsu, M, Chatenoud, L, Wood, K

Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells. by Goto, R, You, S, Zaitsu, M, Chatenoud, L, Wood, K

Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. by Abbs, I, Clark, M, Waldmann, H, Chatenoud, L, Koffman, C, Sacks, S

The induction and maintenance of transplant tolerance engages both regulatory and anergic CD4+ T cells. by Besançon, A, Baas, M, Goncalves, T, Valette, F, Waldmann, H, Chatenoud, L, You, S

Tolerance induction by monoclonal CD3 antibodies is dependent on indoleamine 2,3 dioxygenase (IDO) by Kuhn, C, You, S, Valette, F, Bach, J, Waldmann, H, Chatenoud, L, Grohmann, U

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. by Bolt, S, Routledge, E, Lloyd, I, Chatenoud, L, Pope, H, Gorman, S, Clark, M, Waldmann, H

The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy. by Yamamoto, A, Chernajovsky, Y, Lepault, F, Podhajcer, O, Feldmann, M, Bach, J, Chatenoud, L

Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. by Friend, P, Hale, G, Chatenoud, L, Rebello, P, Bradley, J, Thiru, S, Phillips, J, Waldmann, H

Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. by Kuhn, C, You, S, Valette, F, Hale, G, van Endert, P, Bach, J, Waldmann, H, Chatenoud, L

Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. by You, S, Belghith, M, Cobbold, S, Alyanakian, M, Gouarin, C, Barriot, S, Garcia, C, Waldmann, H, Bach, J, Chatenoud, L

Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target. by You, S, Poulton, L, Cobbold, S, Liu, C, Rosenzweig, M, Ringler, D, Lee, W, Segovia, B, Bach, J, Waldmann, H, Chatenoud, L

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. by Hale, G, Rebello, P, Al Bakir, I, Bolam, E, Wiczling, P, Jusko, W, Vandemeulebroucke, E, Keymeulen, B, Mathieu, C, Ziegler, A, Chatenoud, L, Waldmann, H

Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. by Bestard, O, Crespo, E, Stein, M, Lúcia, M, Roelen, D, de Vaal, Y, Hernandez-Fuentes, M, Chatenoud, L, Wood, K, Claas, F, Cruzado, J, Grinyó, J, Volk, H, Reinke, P

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. by Keymeulen, B, Walter, M, Mathieu, C, Kaufman, L, Gorus, F, Hilbrands, R, Vandemeulebroucke, E, Van de Velde, U, Crenier, L, De Block, C, Candon, S, Waldmann, H, Ziegler, A, Chatenoud, L, Pipeleers, D

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. by Keymeulen, B, Candon, S, Fafi-Kremer, S, Ziegler, A, Leruez-Ville, M, Mathieu, C, Vandemeulebroucke, E, Walter, M, Crenier, L, Thervet, E, Legendre, C, Pierard, D, Hale, G, Waldmann, H, Bach, J, Seigneurin, J, Pipeleers, D, Chatenoud, L

IMMUNOLOGICAL CONSEQUENCES AND TRAFFICKING OF HUMAN REGULATORY MACROPHAGES ADMINISTERED TO RENAL TRANSPLANT RECIPIENTS by Hutchinson, J, Riquelme, P, Sawitzki, B, Tomiuk, S, Miqueu, P, Zuhayra, M, Oberg, H, Pascher, A, Luetzen, U, Janssen, U, Broichhausen, C, Renders, L, Thaiss, F, Scheuermann, E, Henze, E, Volk, H, Chatenoud, L, Lechler, R, Wood, K, Kabelitz, D, Schlitt, H, Geissler, E, Faendrich, F

Cutting edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients by Hutchinson, J, Riquelme, P, Sawitzki, B, Tomiuk, S, Miqueu, P, Zuhayra, M, Oberg, H, Pascher, A, Lützen, U, Janßen, U, Broichhausen, C, Renders, L, Thaiss, F, Scheuermann, E, Henze, E, Volk, H, Chatenoud, L, Lechler, R, Wood, K, Kabelitz, D, Schlitt, H, Geissler, E, Fändrich, F

Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. by Hutchinson, J, Riquelme, P, Sawitzki, B, Tomiuk, S, Miqueu, P, Zuhayra, M, Oberg, H, Pascher, A, Lützen, U, Janssen, U, Broichhausen, C, Renders, L, Thaiss, F, Scheuermann, E, Henze, E, Volk, H, Chatenoud, L, Lechler, R, Wood, K, Kabelitz, D, Schlitt, H, Geissler, E, Fändrich, F

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. by Keymeulen, B, Vandemeulebroucke, E, Ziegler, A, Mathieu, C, Kaufman, L, Hale, G, Gorus, F, Goldman, M, Walter, M, Candon, S, Schandene, L, Crenier, L, De Block, C, Seigneurin, J, De Pauw, P, Pierard, D, Weets, I, Rebello, P, Bird, P, Berrie, E, Frewin, M, Waldmann, H, Bach, J, Pipeleers, D, Chatenoud, L